Background: B-lymphocyte activating antigen B7-1 (hereafter B7), also known as CD80, is a member of the cell surface immunoglobulin superfamily and is expressed on the surface of antigen-presenting cells, including activated B cells, macrophages and dendritic cells. cells As costimulatory ligands, B7-1, which exists mainly as a dimer, and the related protein B7-2 interact with the costimulatory receptors CD28 and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) expressed on T cells, thus forming a . of the dominant pathways that regulate T-cell activation and tolerance, cytokine production and generation of CTLs. The B7/CD28/CTLA4 pathway has the ability to both positively and negatively regulate immune responses. CD80 is thus considered a promising therapeutic target in autoimmune diseases and various carcinomas.The KRIBIOLISA Inhibitor Assay Kits available enable researchers to test the inhibitory effects of various compounds on specific enzymes at a higher output. These assays can help identify or characterize enzyme inhibitors, which is important in early drug discovery and development. They can also be useful in characterizing enzyme activity. These Inhibitor assay kits contain a known inhibitor as a control.
This Assay kit is designed to facilitate the identification and characterization of B7-1 pathway inhibitors.
Assay Features include:
– Ready to use protocol with pre-coated breakapart wells for ease of use
– Standardisation and High Reproducibility
– Lot to Lot Consistency
– Accuracy and Precision
Validated against seven points for a Gold Ring Standard Quality – the benchmark sign for Krishgen quality.
The kits are used for assessing the specific biomarker in samples analyte which may be serum, plasma, biological fluids and cell culture supernatant.
Unlike competitor assays available, we offer pre-coated ready-to-use assays to ensure high level of reproducibility and accuracy.